Key points are not available for this paper at this time.
This Viewpoint compares use and costs of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss between the US and 3 other peer countries.
Vokinger et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: